TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+5.11%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.64B
AUM Growth
+$2.64B
(+2.5%)
Cap. Flow
-$24.4M
Cap. Flow
% of AUM
-0.93%
Top 10 Holdings %
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18
Top Buys
| 1 |
UnitedHealth
UNH
|
$17.9M |
| 2 |
Stryker
SYK
|
$12.2M |
| 3 |
AstraZeneca
AZN
|
$11.8M |
| 4 |
Danaher
DHR
|
$11.6M |
| 5 |
Pfizer
PFE
|
$11.2M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$19M |
| 2 |
SHPG
Shire pic
SHPG
|
$13.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$13.2M |
| 4 |
Abbott
ABT
|
$10.5M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$8.69M |
Sector Composition
| 1 | Healthcare | 92.61% |
| 2 | Real Estate | 3% |
| 3 | Financials | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$140B
| $146M | 5.55% | 2,063,699 | – | – |
|
2
Amgen
AMGN
$155B
| $129M | 4.91% | 700,588 | – | – |
|
3
Biogen
BIIB
$19.4B
| $117M | 4.45% | 403,955 +25,252 | +7% | +$7.33M |
|
4
Johnson & Johnson
JNJ
$427B
| $108M | 4.11% | 893,082 | – | – |
|
|
5
UnitedHealth
UNH
$281B
| $104M | 3.96% | 425,317 +73,000 | +21% | +$17.9M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $99.4M | 3.77% | 1,251,470 -101,372 | -7% | -$8.05M |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $98.8M | 3.75% | 581,522 -32,562 | -5% | -$5.53M |
|
|
8
Pfizer
PFE
$141B
| $85.6M | 3.25% | 2,359,687 +307,744 | +15% | +$11.2M |
|
9
Illumina
ILMN
$15.8B
| $79.5M | 3.02% | 284,492 -10,400 | -4% | -$2.9M |
|
10
Merck
MRK
$210B
| $77.9M | 2.96% | 1,284,022 | – | – |
|
11
Viatris
VTRS
$12.3B
| $59.9M | 2.27% | 1,657,017 -69,950 | -4% | -$2.53M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $54.4M | 2.07% | 438,416 -60,559 | -12% | -$7.52M |
|
13
Regeneron Pharmaceuticals
REGN
$61.5B
| $50.5M | 1.91% | 146,237 +6,677 | +5% | +$2.3M |
|
14
AbbVie
ABBV
$372B
| $47.6M | 1.81% | 513,658 +62,920 | +14% | +$5.83M |
|
15
Incyte
INCY
$16.5B
| $43.2M | 1.64% | 645,442 | – | – |
|
|
AGN
16
DELISTED
Allergan plc
AGN
| $41.5M | 1.57% | 248,836 | – | – |
|
|
17
Abbott
ABT
$231B
| $38.2M | 1.45% | 627,019 -171,600 | -21% | -$10.5M |
|
18
Medtronic
MDT
$119B
| $36.3M | 1.38% | 423,693 -98,518 | -19% | -$8.43M |
|
19
Bristol-Myers Squibb
BMY
$96B
| $36M | 1.37% | 651,030 +125,308 | +24% | +$6.93M |
|
20
Eli Lilly
LLY
$657B
| $33.3M | 1.26% | 390,108 -96,757 | -20% | -$8.26M |
|
21
Thermo Fisher Scientific
TMO
$186B
| $31.6M | 1.2% | 152,695 +4,840 | +3% | +$1M |
|
22
Humana
HUM
$36.5B
| $31.3M | 1.19% | 105,053 -13,680 | -12% | -$4.07M |
|
|
23
Sarepta Therapeutics
SRPT
$1.78B
| $31M | 1.18% | 234,489 -144,027 | -38% | -$19M |
|
24
Idexx Laboratories
IDXX
$51.8B
| $28.2M | 1.07% | 129,608 -23,468 | -15% | -$5.11M |
|
|
25
AstraZeneca
AZN
$248B
| $27.3M | 1.04% | 778,888 +336,288 | +76% | +$11.8M |
|